Having trouble accessing articles? Reset your cache.

Linagliptin: Phase III data

In a double-blind Phase III trial in 227 Type II diabetics for whom metformin therapy is inappropriate, once-daily 5 mg oral linagliptin as monotherapy met the primary endpoint of significantly

Read the full 300 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE